Longitudinal and cross sectional assessments of health utility in adults with HIV/AIDS: A systematic review and meta-analysis Quality, performance, safety and outcomes

BMC Health Services Research

Volumn 15, Issue 1, 2015, Pages

  Tran, Bach Xuan ^a,b   Nguyen, Long Hoang ^c   Ohinmaa, Arto ^d   Maher, Rachel Marie ^b   Nong, Vuong Minh ^b   Latkin, Carl A ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b HANOI MEDICAL UNIVERSITY   (Viet Nam)

^c VIETNAM NATIONAL UNIVERSITY   (Viet Nam)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

HIV; Longitudinal meta analysis; Quality of life; Systematic review; Utility

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; FEMALE; HEALTH CARE DELIVERY; HIV INFECTIONS; HUMAN; LONGITUDINAL STUDY; MALE; META ANALYSIS; MIDDLE AGED; PATIENT ATTITUDE; QUALITY OF LIFE; REGRESSION ANALYSIS; REPRODUCIBILITY; STATISTICAL ANALYSIS; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-RETROVIRAL AGENTS; CROSS-SECTIONAL STUDIES; DATA INTERPRETATION, STATISTICAL; DELIVERY OF HEALTH CARE; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; QUALITY OF LIFE; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS;

EID: 84925450358     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/s12913-014-0640-z     Document Type: Article

References (77)

1. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach, 2006 Revision. Geneva: World Health Organization; 2006.
2. WHO. Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Geneva: World Health Organization; 2009.
3. Lin MK, Wu AW, Revicki DA. Incorporating quality of life measures in HIV clinical trials. HIV Clin Trials. 2002;3(3):202-18.
4. Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making. 2002;22(1):27-38.
5. Aranda-Naranjo B. Quality of life in the HIV-positive patient: implications and consequences. J Assoc Nurses AIDS Care. 2004;15(5 Suppl):20S-7S.
6. Kudel I, Farber SL, Mrus JM, Leonard AC, Sherman SN, Tsevat J. Patterns of responses on health-related quality of life questionnaires among patients with HIV/AIDS. J Gen Intern Med. 2006;21 Suppl 5:S48-55.
7. Feeny D. A utility approach to the assessment of health-related quality of life. Med Care. 2000;38(9 Suppl):II151-4.
8. Drummond F, Sculpher J, Torrance W, O'Brien J, Stoddart L. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 2005.
9. Garvie PA, Lawford J, Banet MS, West RL. Quality of life measurement in paediatric and adolescent populations with HIV: a review of the literature. Child Care Health Dev. 2009;35(4):440-53.
10. Robinson FP. Measurement of quality of life in HIV disease. J Assoc Nurses AIDS Care. 2004;15(5 Suppl):14S-9S.
11. Clayson DJ, Wild DJ, Quarterman P, Duprat-Lomon I, Kubin M, Coons SJ. A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials. PharmacoEconomics. 2006;24(8):751-65.
12. Grossman HA, Sullivan PS, Wu AW. Quality of life and HIV: current assessment tools and future directions for clinical practice. AIDS Read. 2003;13(12):583-90. 595-587.
13. Wu AW. Quality of life assessment comes of age in the era of highly active antiretroviral therapy. AIDS. 2000;14(10):1449-51.
14. Joish VN, Oderda GM. Cost-utility analysis and quality adjusted life years. J Pain Palliat Care Pharmacother. 2005;19(1):57-61.
15. Hornberger J, Holodniy M, Robertus K, Winnike M, Gibson E, Verhulst E. A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy. Med Decis Making. 2007;27(6):789-821.
16. Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making. 2002;22(6):475-81.
17. Lara AM, Wakholi BN, Kasirye A, Munderi P, Watera C, Lalloo DG, et al. Utility assessment of HIV/AIDS-related health states in HIV-infected Ugandans. AIDS. 2008;22 Suppl 1:S123-30.
18. Stavem K, Froland SS, Hellum KB. Comparison of preference-based utilities of the 15D, EQ-5D and SF-6D in patients with HIV/AIDS. Qual Life Res. 2005;14(4):971-80.
19. Tsevat J, Sherman SN, McElwee JA, Mandell KL, Simbartl LA, Sonnenberg FA, et al. The will to live among HIV-infected patients. Ann Intern Med. 1999;131(3):194-8.
20. de Boer JB, van Dam FS, Sprangers MA. Health-related quality-of-life evaluation in HIV-infected patients. Rev Lit PharmacoEcon. 1995;8(4):291-304.
21. Vanhems P, Toma E, Pineault R. Quality of life assessment and HIV infection: a review. Eur J Epidemiol. 1996;12(3):221-8.
22. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336-41.
23. Centers for Disease Control and Prevention. Revised Surveillance Case Definitions for HIV Infection Among Adults, Adolescents, and Children Aged <18 Months and for HIV Infection and AIDS Among Children Aged 18 Months to <13 Years - United States, 2008. In: Atlanta, USA. 2008.
24. Sophia Rabe-Hesketh, Anders Skrondal. Multilevel and longitudinal modeling using Stata. Stata Press Publication StataCorp LP 2005
25. Kalaian HA, Raudenbush SW. A multivariate mixed linear model for meta-analysis. Psychol Meth. 1996;1(2):227-35.
26. Nosyk B, Sun H, Bansback N, Guh DP, Li X, Barnett P, et al. The concurrent validity and responsiveness of the health utilities index (HUI 3) among patients with advanced HIV/AIDS. Qual Life Res. 2009;18(7):815-24.
27. Wu AW, Jacobson KL, Frick KD, Clark R, Revicki DA, Freedberg KA, et al. Validity and responsiveness of the euroqol as a measure of health-related quality of life in people enrolled in an AIDS clinical trial. Qual Life Res. 2002;11(3):273-82.
28. Delate T, Coons SJ. The use of 2 health-related quality-of-life measures in a sample of persons infected with human immunodeficiency virus. Clin Infect Dis. 2001;32(3):E47-52.
29. Miners AH, Sabin CA, Mocroft A, Youle M, Fisher M, Johnson M. Health-related quality of life in individuals infected with HIV in the era of HAART. HIV Clin Trials. 2001;2(6):484-92.
30. Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;170(11):1212-7.
31. Tillmann HL, Manns MP, Claes C, Heiken H, Schmidt RE, Stoll M. GB virus C infection and quality of life in HIV-positive patients. AIDS Care. 2004;16(6):736-43.
32. Huang IC, Willke RJ, Atkinson MJ, Lenderking WR, Frangakis C, Wu AW. US and UK versions of the EQ-5D preference weights: does choice of preference weights make a difference? Qual Res Int. 2007;16(6):1065-72.
33. Louwagie GM, Bachmann MO, Meyer K, Booysen Fle R, Fairall LR, Heunis C. Highly active antiretroviral treatment and health related quality of life in South African adults with human immunodeficiency virus infection: A cross-sectional analytical study. BMC Public Health. 2007;7:244.
34. Bansback N, Sun H, Guh DP, Li X, Nosyk B, Griffin S, et al. Impact of the recall period on measuring health utilities for acute events. Health Econ. 2008;17(12):1413-9.
35. Anis AH, Nosyk B, Sun H, Guh DP, Bansback N, Li X, et al. Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events. J Acquir Immune Defic Syndr. 2009;51(5):631-9.
36. Lopez-Bastida J, Oliva-Moreno J, Perestelo-Perez L, Serrano-Aguilar P. The economic costs and health-related quality of life of people with HIV/AIDS in the Canary Islands, Spain. BMC Health Serv Res. 2009;9:55.
37. Sakthong P, Schommer JC, Gross CR, Prasithsirikul W, Sakulbumrungsil R. Health utilities in patients with HIV/AIDS in Thailand. Value Health. 2009;12(2):377-84.
38. Bhargava A, Booysen Fle R. Healthcare infrastructure and emotional support are predictors of CD4 cell counts and quality of life indices of patients on antiretroviral treatment in Free State Province, South Africa. AIDS Care. 2010;22(1):1-9.
39. Tran BX, Ohinmaa A, Nguyen LT, Nguyen TA, Nguyen TH. Determinants of health-related quality of life in adults living with HIV in Vietnam. AIDS Care. 2011;23(10):1236-45.
40. Joyce VR, Barnett PG, Chow A, Bayoumi AM, Griffin SC, Sun H, et al. Effect of treatment interruption and intensification of antiretroviral therapy on health-related quality of life in patients with advanced HIV: a randomized, controlled trial. Med Decis Making. 2012;32(1):70-82.
41. Gow J, George G, Govender K. A comparison of quality of life between HIV positive and negative diamond miners in South Africa. SAHARA J. 2013;10(2):89-95.
42. Kempen JH, Martin BK, Wu AW, Barron B, Thorne JE, Jabs DA. The effect of cytomegalovirus retinitis on the quality of life of patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology. 2003;110(5):987-95.
43. Oliva J, Roa C, del Llano J. Indirect costs in ambulatory patients with HIV/AIDS in Spain: a pilot study. PharmacoEconomics. 2003;21(15):1113-21.
44. Oliva-Moreno J, Lopez-Bastida J, Worbes-Cerezo M, Serrano-Aguilar P. Health related quality of life of Canary Island citizens. BMC Public Health. 2010;10:675.
45. Puhan MA, Ahuja A, Van Natta ML, Ackatz LE, Meinert C. Interviewer versus self-administered health-related quality of life questionnaires - does it matter? Health Qual Life Outcomes. 2011;9:30.
46. Kittikraisak W, Kingkaew P, Teerawattananon Y, Yothasamut J, Natesuwan S, Manosuthi W, et al. Health related quality of life among patients with tuberculosis and HIV in Thailand. PLoS One. 2012;7(1):e29775.
47. Joyce VR, Barnett PG, Bayoumi AM, Griffin SC, Kyriakides TC, Yu W, et al. Health-related quality of life in a randomized trial of antiretroviral therapy for advanced HIV disease. J Acquir Immune Defic Syndr. 2009;50(1):27-36.
48. Tran BX, Ohinmaa A, Nguyen LT. Quality of life profile and psychometric properties of the EQ-5D-5L in HIV/AIDS patients. Health Qual Life Outcomes. 2012;10:132.
49. Isogai PK, Rueda S, Rachlis AR, Rourke SB, Mittmann N, Team OCS. Prediction of health preference values from CD4 counts in individuals with HIV. Med Decis Making. 2013;33(4):558-66.
50. Weaver MR, Conover CJ, Proescholdbell RJ, Arno PS, Ang A, Uldall KK, et al. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders. J Mental Health Policy Econ. 2009;12(1):33-46.
51. Aden B, Nosyk B, Wittenberg E, Schackman BR. Health-related quality of life in HIV-infected and at-risk women: the impact of illicit drug use and hepatitis C on a community preference weighted measure. Med Decis Making. 2013;34:800-8.
52. Surah S, Adams R, Townsend L, Reynolds I, Kinahan JC, Keating S, et al. Health-related quality of life of HIV-infected intravenous drug users. Int J STD AIDS. 2013;24(11):867-74.
53. Lenert LA, Feddersen M, Sturley A, Lee D. Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection. Am J Med. 2002;113(3):229-32.
54. Mrus JM, Sherman KE, Leonard AC, Sherman SN, Mandell KL, Tsevat J. Health values of patients coinfected with HIV/hepatitis C: are two viruses worse than one? Med Care. 2006;44(2):158-66.
55. Fang CT, Chang YY, Hsu HM, Twu SJ, Chen KT, Chen MY, et al. Cost-effectiveness of highly active antiretroviral therapy for HIV infection in Taiwan. J Formos Med Assoc. 2007;106(8):631-40.
56. Mrus JM, Leonard AC, Yi MS, Sherman SN, Fultz SL, Justice AC, et al. Health-related quality of life in veterans and nonveterans with HIV/AIDS. J Gen Intern Med. 2006;21 Suppl 5:S39-47.
57. Honiden S, Sundaram V, Nease RF, Holodniy M, Lazzeroni LC, Zolopa A, et al. The effect of diagnosis with HIV infection on health-related quality of Life. Qual Life Res. 2006;15(1):69-82.
58. Jelsma J, Maclean E, Hughes J, Tinise X, Darder M. An investigation into the health-related quality of life of individuals living with HIV who are receiving HAART. AIDS Care. 2005;17(5):579-88.
59. Martin BK, Wu AW, Gelman R, Mitsuyasu RT, Adult ACTG. Quality of life in a clinical trial of highly active antiretroviral therapy alone or with intravenous or subcutaneous interleukin-2 administration. J Acquir Immune Defic Syndr. 2005;40(4):428-33.
60. Tillmann HL, Kaiser T, Claes C, Schmidt RE, Manns MP, Stoll M. Differential influence of different hepatitis viruses on quality of life in HIV positive patients. Eur J Med Res. 2006;11(9):381-5.
61. Mathews WC, May S. EuroQol (EQ-5D) measure of quality of life predicts mortality, emergency department utilization, and hospital discharge rates in HIV-infected adults under care. Health Qual Life Outcomes. 2007;5:5.
62. Burman WJ, Grund B, Roediger MP, Friedland G, Darbyshire J, Wu AW, et al. The impact of episodic CD4 cell count-guided antiretroviral therapy on quality of life. J Acquir Immune Defic Syndr. 2008;47(2):185-93.
63. Babikako HM, Neuhauser D, Katamba A, Mupere E. Feasibility, reliability and validity of health-related quality of life questionnaire among adult pulmonary tuberculosis patients in urban Uganda: cross-sectional study. Health Qual Life Outcomes. 2010;8:93.
64. Gianotti N, Galli L, Bocchiola B, Cahua T, Panzini P, Zandona D, et al. Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy. HIV Med. 2013;14(3):153-60.
65. Carr A, Chuah J, Hudson J, French M, Hoy J, Law M, et al. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. AIDS. 2000;14(9):1171-80.
66. Coplan PM, Cook JR, Carides GW, Heyse JF, Wu AW, Hammer SM, et al. Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine. Clin Infect Dis. 2004;39(3):426-33.
67. Hughes J, Jelsma J, Maclean E, Darder M, Tinise X. The health-related quality of life of people living with HIV/AIDS. Disabil Rehabil. 2004;26(6):371-6.
68. Thein H, Maruff P, Krahn M, Kaldor J, Koorey D, Brew B, et al. Cognitive function, mood and health-related quality of life in hepatitis C virus (HCV)-monoinfected and HIV/HCV-coinfected individuals commencing HCV treatment. HIV Med. 2007;8(3):192-202.
69. Hubben GA, Bishai D, Pechlivanoglou P, Cattelan AM, Grisetti R, Facchin C, et al. The societal burden of HIV/AIDS in Northern Italy: an analysis of costs and quality of life. AIDS Care. 2008;20(4):449-55.
70. Harding R, Clucas C, Lampe FC, Date HL, Fisher M, Johnson M, et al. What factors are associated with patient self-reported health status among HIV outpatients? A multi-centre UK study of biomedical and psychosocial factors. AIDS Care. 2012;24(8):963-71.
71. Dowdy DW, Israel G, Vellozo V, Saraceni V, Cohn S, Cavalcante S, et al. Quality of life among people treated for tuberculosis and human immunodeficiency virus in Rio de Janeiro, Brazil. Int J Tubercul Dis. 2013;17(3):345-7.
72. Morimoto T, Fukui T. Utilities measured by rating scale, time trade-off, and standard gamble: review and reference for health care professionals. J Epidemiol. 2002;12(2):160-78.
73. Doth AH, Hansson PT, Jensen MP, Taylor RS. The burden of neuropathic pain: A systematic review and meta-analysis of health utilities. Pain. 2010;149(2):338-44.
74. Garza AG, Wyrwich KW. Health utility measures and the standard gamble. Acad Emerg Med. 2003;10(4):360-3.
75. Tsevat J, Goldman L, Soukup JR, Lamas GA, Connors KF, Chapin CC, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 1993;13(2):161-5.
76. Webb A, Norton M. Clinical assessment of symptom-focused health-related quality of life in HIV/AIDS. J Assoc Nurses AIDS Care. 2004;15(2):67-78. quiz 79-81.
77. WHOQOL HIV Group. WHOQOL-HIV for quality of life assessment among people living with HIV and AIDS: results from the field test. AIDS Care. 2004;16(7):882-9.